Cargando…
Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy
KRAS is the most commonly mutated oncogene in human cancers and is associated with poor prognosis and drug resistance. Let-7 is a family of tumor suppressor microRNAs that are frequently suppressed in solid tumors, where KRAS mutations are highly prevalent. In this study, we investigated the potenti...
Autores principales: | Dai, Xin, Jiang, Ying, Tan, Chalet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422443/ https://www.ncbi.nlm.nih.gov/pubmed/25946136 http://dx.doi.org/10.1371/journal.pone.0126653 |
Ejemplares similares
-
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010) -
miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy
por: Tang, Huan, et al.
Publicado: (2019) -
A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis
por: Grechukhina, Olga, et al.
Publicado: (2012) -
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
por: Del Re, Marzia, et al.
Publicado: (2017) -
KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)